Ultra-Low-Flow Anesthesia and Carbon Footprint (NCT07313969) | Clinical Trial Compass
CompletedNot Applicable
Ultra-Low-Flow Anesthesia and Carbon Footprint
Turkey (Türkiye)92 participantsStarted 2025-12-30
Plain-language summary
This is a prospective, randomized controlled clinical trial evaluating the effects of ultra-low fresh gas flow (0.5 L/min) versus normal fresh gas flow (2.0 L/min) sevoflurane anesthesia in adult patients undergoing on-pump cardiac surgery. The study aims to determine whether ultra-low-flow anesthesia can be used safely to reduce volatile anesthetic consumption and environmental emissions without compromising hemodynamic stability or anesthetic depth.
Eligible adult patients scheduled for elective coronary artery bypass grafting (CABG) or valve surgery under general anesthesia will be randomized in a 1:1 ratio to one of two groups: ultra-low-flow (0.5 L/min) or normal-flow (2.0 L/min). All other anesthetic techniques, including induction drugs, ventilation parameters, temperature management, and perfusion strategies, will be standardized.
The primary outcome is the total amount of sevoflurane consumed per case. Secondary outcomes include intraoperative hemodynamic parameters (heart rate, mean arterial pressure), depth of anesthesia (BIS/MAC values), postoperative recovery times, and estimated carbon dioxide equivalent (CO₂e) emissions.
Outcome assessors and data analysts will remain blinded to group allocation. The findings of this study are expected to provide new evidence regarding the safety, efficiency, and environmental benefits of ultra-low-flow anesthesia techniques in cardiac surgery.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult patients aged 18-80 years
* Scheduled for elective on-pump CABG or valve surgery
* ASA physical status II-III
* Written informed consent obtained
Exclusion Criteria:
* Emergency surgery
* Severe hepatic or renal dysfunction
* Known allergy to volatile anesthetics
* Significant pulmonary disease (e.g., COPD with GOLD III-IV)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial studied ultra-low-flow anesthesia during cardiac surgery — if I need cardiac surgery, is ultra-low-flow anesthesia an option at my hospital, and would it be appropriate for my specific situation?
2Since this study measured how much sevoflurane was used per case, what does the amount of anesthetic gas used actually mean for my safety or recovery during cardiac surgery?
3This trial is already completed — has my care team seen the results, and do those results influence how they currently choose anesthesia flow rates for cardiac procedures like mine?
4Sevoflurane is used to keep patients unconscious during surgery — are there other anesthetic options my team might consider for my cardiac surgery, and how do they compare in terms of safety and environmental impact?
5Since this was categorized as 'not applicable' for phase, meaning it wasn't testing a new drug but rather a practice approach, does my hospital already use ultra-low-flow techniques, or is standard-flow anesthesia still the norm here?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Total sevoflurane consumption (mL per case), measured at the end of surgery.
Timeframe: throughout the surgery
Trial details
NCT IDNCT07313969
SponsorDr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital